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INHIBITION OF ANGIOGENESIS 
ASSOCIATED WITH OVARIAN CANCER BY 
NANOPARTICLES OF CERIUM OXIDE 
RELATED APPLICATION 
2 
tive free radical scavengers in biological systems [3,4,5]. 
These regenerative antioxidant properties are due, in part, to 
the valence structure of the cerium atom combined with 
inherent defects in the crystal lattice structure, which are 
magnified at the nano scale. It has been suggested that the 
unique structure of engineered cerium oxide nanoparticles, 
with respect to valence and oxygen defects, promotes cell 
longevity and decreases toxic insults by virtue of its antioxi-
dant effects that occur when the nanoparticles enter the cells 
This application is a continuation-in-part of and claims 
priority from co-pending nonprovisional application Ser. No. 
12/429,650, which was filed on 24 Apr. 2009, claiming pri-
ority to provisional application Ser. No. 61/125,602, filed on 
25 Apr. 2008, both of which are incorporated herein by ref-
erence in their entirety. 
10 [6] preventing the accumulation of reactive oxygen species 
(ROS) in cell [3]. 
STATEMENT OF GOVERNMENT RIGHTS 
Tumor angiogenesis is characterized by the formation of 
new, irregular blood vessels from a preexisting vascular net-
work. This abnormal angiogenesis is required for the growth, 
The invention claimed herein was made with at least partial 
support from the U.S. Government. Accordingly, the govern-
ment may have certain rights in the invention, as specified by 
law. 
15 survival, and metastasis of most solid tumors [7,8]. Vascular 
endothelial growth factor (VEGF) is one of the most impor-
tant proangiogenic factors, which acts as a mitogen for vas-
cular endothelial cells in vitro and as an angiogenic factor in 
vivo [9]. It is over expressed in various human cancers [10, 11, 
FIELD OF THE INVENTION 
The present invention relates to the field of cancerous dis-
eases and, more particularly, to nanoparticles of cerium oxide 
and their use in a treatment which inhibits angiogenesis asso-
ciated with the cancer. 
20 12, 13] including ovarian cancer. Recently it has been sug-
gested that ROS played an important role in regulating tumor 
induced angiogenesis by controlling VEGF production. 
Enhanced production ofVEGF has been shown to correlate 
with a poor outcome for patients with both early and 
BACKGROUND OF THE INVENTION 
25 advanced OvCa. Various anti-angiogenic agents have been 
and are undergoing evaluations in ovarian cancer clinical 
trials. A phase II study of single-agent bevacizumab (a mono-
clonal antibody directed against VEGF) showed promising 
results [14]. Therefore, VEGF signaling is becoming the 
In the United States, 27,000 women are newly diagnosed 
and approximately 14, 000 women die from ovarian cancer 
(OvCa) annually [1]. Such high mortality rates are due to 
majority of patients (75%) presenting with advanced (stage 
30 focus of antiangiogenesis-targeted therapies in ovarian can-
III or greater) disease at the time of diagnosis [2]. More than 
90% of the patients have better prognosis if the cancer is 35 
detected in its earliest stages. Treatment of epithelial ovarian 
cancer generally involves surgical debulking followed by 
chemotherapy with a combination of platinum and a taxane-
containing agent. However, majority of patients recur and 
ultimately succumb to their cancer. Consequently, there is a 40 
vast need to develop new therapeutics that can be more effec-
tive in treating ovarian cancer and delaying or preventing 
recurrences. Novel therapies that target ovarian tumorigen-
esis are extensively been researched, but we have yet to come 
cer. 
The present disclosure concerns the novel approach of 
using cerium oxide nanoparticles as a therapeutic agent for 
ovarian cancer treatment. Our data demonstrate that NCe was 
able to curtail ovarian cancer growth, migration and invasion 
and its main mechanism of action appears to be via inhibition 
of angiogenesis by targeting the endothelial cells 
SUMMARY OF THE INVENTION 
Ovarian cancer is the fifth most common cause of death 
among women in the U.S. and the leading cause of death from 
gynecological malignancies. There is an urgent need for 
novel therapies to counteract the high mortality rate associ-
up with a promising drug. 45 ated with OvCa. We have developed and engineered nanopar-
ticles of cerium oxide for a potential nanotherapeautic for 
ovarian cancer treatment. Here, we show for the first time that 
the NCe attenuated growth factor (SDFl, HB-EGF, 
Nanotechnology based tools and techniques are rapidly 
emerging in the fields of medical imaging and targeted drug 
delivery. Cerium oxide is a rare-earth oxide that is found in 
the lanthanide series of the periodic table. Nanocrystalline 
cerium oxide (nanoceria) exhibits a blue shift in the ultravio- 50 
let absorption spectrum, the shifting and broadening of 
Raman allowed modes and lattice expansion as compared to 
bulk cerium oxide indicating its unique properties. Nanopar-
ticulate cerium oxide, also known as nanoceria or NCe, has 
emerged as a fascinating and lucrative material in biomedical 55 
science due to its unique ability to switch oxidation states 
between (III) and (IV) depending upon the environment. The 
ability to switch between mixed oxidation states of nanoceria 
is comparable to biological antioxidants. This imparts nano-
ceria with a very important biological property of radical 60 
scavenging which can be tuned based upon the retention of 
oxygen vacancies (defects) and concentration ofCe3 + species 
in nanoceria. The reversibility of oxidation state is the key 
property in making nanoceria a potent antioxidant, thereby 
eliminating the need for repeated dosage. Previous studies 65 
have demonstrated that cerium oxide nanoparticles possess 
excellent antioxidant properties and act as potent, regenera-
VEGF165 and HGF) induced cell migration and invasion of 
SKOV3 cells, without affecting the cell proliferation. For 
investigating the preclinical in vivo therapeutic potential of 
NCe, humanA2780 ovarian cancer cells were injected intra-
peritoneally in nude mice and NCe (0.1 mg/kg body weigh) 
was administered intra-peritoneally every third day for 4 
weeks. NCe treated mice showed significant reduction 
(p<0.002) in the tumor growth accompanied by decreased 
tumor cell proliferation as evident from the tumor size and 
Ki67 staining. Reduction of the tumor mass was accompanied 
by attenuation of angiogenesis, as observed by reduced CD31 
staining and CD31 positive count in xenografts from treated 
mice. Further examination of NCe's anti-angiogenic prop-
erty, revealed that NCe inhibited VEGF 165 induced prolifera-
tion, capillary tube formation and activation ofVEGFR2 and 
MMP2 in human umbilical vascular endothelial cells. Col-
lectively, these results indicate that cerium oxide based NCe 
is a novel nanoparticle that can potentially be used as an 
anti-angiogenic therapeutic agent in ovarian cancer 
US 8,916,199 Bl 
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With the foregoing in mind, the present invention advan-
tageously provides a method of treating ovarian cancer in a 
mammal, the method comprising parenteral administration to 
the mammal of an effective amount of cerium oxide nanopar-
ticles having a predominance of Ce+3 . The marmnal is pref-
erably a human subject. Parenteral administration of the 
cerium oxide nanoparticles is a preferred route of adminis-
tration, particularly intraperitoneal administration. In the 
method, an effective amount comprises less than approxi-
mately 1 mgperkilogramofbodyweightofthemammaland 10 
most preferably comprises approximately 0.1 mg per kilo-
gram of body weight of the mammal. In the method, the 
effective amount is preferably parenterally administered 
approximately every 72 hours. 
Alternate embodiments of the invention include a method 15 
4 
as % of control. The data is represents three separate experi-
ments done in triplicates. NS: not significant, compared to 
untreated cells at respective time point. B. For colony forma-
tion, 2000 cells/well (A2780, C200 and SKOV3) were plated 
in 6-well plates and treated with indicated concentrations of 
NCe, every third day for 2 weeks until colonies were formed. 
The colonies were stained with MTT and counted. The data 
represents three separate experiments done in triplicates. NS: 
not significant compared to untreated cells. 
FIG. 3: Illustrates that NCe treatment attenuated cell 
migration and invasion in ovarian cancer cell. A. Effect of 
NCe on various growth factors mediated cell migration was 
examined using wound closure assay as described in Material 
and Methods. Percent migration was calculated by measuring 
the length and the width of the cell free area. The width was 
measured at three different points along the scratch area and 
then averaged to get an accurate representation of the entire 
scratch. Percent migrated area was determined by using the 
formula [area at 0 time/area+GF]xlOO. Results are shown as 
of inhibiting marmnalian ovarian cells, the method compris-
ing contacting the cells with an effective amount of cerium 
oxide nanoparticles having a predominance ofCe+3 . Another 
embodiment includes a method of inhibiting angiogenesis 
associated with a mammalian ovarian carcinoma, the method 
comprising contacting the carcinoma with an effective 
amount of cerium oxide nanoparticles having a predomi-
nance of Ce+3 . Contacting the carcinoma preferably com-
prises contacting vascular endothelial cells associated with 
the carcinoma. 
20 mean±S.D. of n=7. B. To examine effect ofNCe on invasion, 
1xl05 SKOV3 cells were seeded into the upper wells with 100 
µM NCe in the FIA chamber in 500 µl culture medium. 
Various growth factors (EGF, VEGF 165 and SD Fl) (25 ng/ml) 
was added to the underlying media. 24 hrs later, invasion was 
The invention additionally discloses a composition of mat-
ter comprising nanoparticles of cerium oxide wherein Ce3+ 
predominates over Ce4 +. The nanoparticles preferably com-
prise a particle size of from approximately 25 µM to approxi-
mately 50 µMand wherein Ce3 + predominates over Ce4 +. 
BRIEF DESCRIPTION OF THE DRAWINGS 
Some of the features, advantages, and benefits of the 
present invention having been stated, others will become 
apparent as the description proceeds when taken in conjunc-
tion with the accompanying drawings, presented for solely 
for exemplary purposes and not with intent to limit the inven-
tion thereto, and in which: 
FIG. 1 Shows Preparation and characterization ofNCe. A. 
UV-visible graph of ceria nanoparticles taken after one week 
of aging (cerium 3+ and cerium 4+ transmission plots are 
shown for reference); B. XPS spectrum of ceria nanoparticles 
showing the binding energy region of cerium and proves the 
presence of both cerium (III) and cerium (IV) species. The 
peaks between 87 5 to 895 e V belong to Ce 3d5/2 degenerate 
levels; C. High resolution transmission electron micrograph 
25 determined following manufacturer's instructions. Results 
are shown as mean±S.D. of triplicates. ***p<0.001 growth 
factor treated compared to control. $$$p<0.001 NCe treated 
compared to growth factor. 
FIG. 4: NCe treatment restricted ovarian tumor growth in 
30 vivo. A. Gross morphology of representative mouse with 
tumors at day 30 (n=6). B Cumulative abdominal circumfer-
ence at the end of the study. C. Excised tumor weight from 
vehicle (PBS) treated and NCe (0.1 mg/kg bd wt; every third 
day). D. (i) Representative H&E (x20) photomicrographs 
35 exhibiting live (purple) and necrotic (pink, encircled) areas in 
untreated and treated xenografts. (ii) Graphical representa-
tion of viable tumor size measured as described in Material 
and Methods. E. (i) Representative Ki-67 staining (x200) of 
excised A2780 xenografts at day 30. (ii) Count of positive 
40 Ki-67 cells from 5 high powered fields (x400) in 3 different 
xenografts from each group. Counts are expressed as percent-
age of control. 
FIG. 5: NCe treatment is non-toxic in nude mice. After 
sacrificing animal groups (n=6) at the end of the study (day 
45 30), blood was collected in heparin coated tubes and plasma 
was prepared. A panel ofliver and kidney cytotoxic tests were 
performed in plasma prepared from control and NCe treated 
mice as per the manufacturer's instructions, A. ALT (Alanine 
Transaminase), B. AST (Aspartate Transaminase), C. Albu-
of ceria nanoparticles showing the presence of individual 3-5 
nm particles in 10-15 nm agglomerate. The inset confirms the 
fluorite structure of nanoceria; D. Basal levels of ROS in 
ovarian cancer cell line. A2780 cells were treated with NCe 
(50-100 µM) for 48 h. Cells were washed with PBS and 
loaded with DCF-DA dye (5 µM) and fluorescence was 
recorded at excitation 485 nm and emission 530 nm for vari-
ous time periods (5-60 min). Wells containing only cells 55 
without DCFDA dye (cross) or without cells containing 
DCFDA dye (filled diamond) were used as a blank; E. Bar 
graph represents ROS levels at the 60 min of treatment with 
DCF-DA dye. Results are shown as mean±S.D. of 4 samples. 
***p<0.001 NCe at 100 µM; *p<0.05 NCe compared to 60 
untreated cells. 
50 min, D. BUN (Blood Urea Nitrogen), E. Creatinine and F. 
Glucose. 
FIG. 6: NCe inhibits metastasis and vessel formation in 
A2780 xenografts. A. Representative H&E (xlOO) photomi-
crograph depicting lung metastatic nodules from Untreated 
and NCe treated mice (arrows point to metastatic nodules). B. 
Enumeration of metastatic nodules found per lung from 
Untreated and NCe treated mice. Total of 5 lung sections were 
observed to get the average count. *p<0.005 NCe compared 
to untreated. C. Representative photomicrograph of CD31 
staining of blood microvessels ( x200) inA2780 xenografts at 
day 30. D. Count ofaveragemicrovessels per high power field 
(x400) from five fields of three xenograft section from 
untreated and NCe treated mice. ***p<0.001, NCe treated to 
untreated. 
FIG. 2 Shows that NCe treatment did not affect prolifera-
tion and colony formation in ovarian cancer cell lines. A. 
Various ovarian cancer cell lines (A2780, C200 and SKOV3), 
were plated in 96 well plates (5xl04 cells/well) and treated 65 
with indicated doses of NCe (25-200 µM). Post 72 h MTT 
assay was performed to estimate live cells. The data is plotted 
FIG. 7: NCe treatment inhibits VEGF induced downstream 
signaling in endothelial cells. A. HUVEC cells were treated 
with indicated concentrations ofNCe and VEGF. DNA syn-
US 8,916,199 Bl 
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thesis was measured by [3 H]-thymidine incorporation (n=4). 
***, p<0.001; NS not significant compare with untreated 
cells. $, p<0.05; $$$, p<0.001 compared with VEGF treated 
cells. B. To examine the effect ofNCe on tube formation in 
HUVEC cells, matrigel matrix was uniformly plated onto 5 
8-well chamber slides (0.15 ml) andincubatedat37° C. for30 
min. During the incubation time, HUVEC cells in T75 flasks 
were washed with PBS and digested with 1 x trypsin solution 
for about 3 min, and suspended in growth factors free 
medium. The cells were counted and diluted to 2xl05/ml in 10 
6 
DETAILED DESCRIPTION OF THE PREFERRED 
EMBODIMENT 
The present invention will now be described more fully 
hereinafter with reference to the accompanying drawings, in 
which preferred embodiments of the invention are shown. 
Unless otherwise defined, all technical and scientific terms 
used herein are intended to have the same meaning as com-
monly understood in the art to which this invention pertains 
and at the time of its filing. Although various methods and 
materials similar or equivalent to those described herein can 
be used in the practice or testing of the present invention, 
suitable methods and materials are described below. How-
ever, the skilled should understand that the methods and 
medium. To set up the tube formation assay, cells were treated 
with NCe (25-50 µM) was mixed with cells in the presence or 
absence ofVEGF 165 (25 ng/ml) and transferred to each well 
(200 µl) coated with matrigel. The plates or slides were incu-
bated at 37° C. for 16 hand imaged under a phase contrast 
inverted microscope at 1 Ox objective magnification. C. To 
examine the effect ofNCe treatment on VEGF induced phos-
phorylation of VEGFR2 (Yl 175 and Y951) serum-starved 
HUVECs were treated with or without NCe (25-50 µM) and 
then stimulated with 25 ng/ml VEGF for 5-30 minutes. 
Immunoblottingwas performed with p VEGFR2(Yl175) and 
actin antibodies for protein loading control. D. To evaluate the 
effect of NCe on VEGF induced MMP2 activity, HUVEC 
cells were treated with NCe (25-50 µM) in the presence or 
absence ofVEGFl 65 (25 ng/ml). Post 24 h ofincubation, cell 
supernatant was processed for zymography assay as 
described in methods. 
15 materials used and described are examples and may not the 
only ones suitable for use in the invention. 
Moreover, it should also be understood that any tempera-
ture, weight, volume, time interval, pH, salinity, molarity or 
molality, range, concentration and any other measurements, 
20 quantities or numerical expressions given herein are intended 
to be approximate and not exact or critical figures unless 
expressly stated to the contrary. Accordingly, where appro-
priate to the invention and as understood by those of skill in 
the art, it is proper to describe the various aspects of the 
FIG. 8: NCe treatment potentiates the endothelial apopto-
25 invention using approximate or relative terms and terms of 
degree commonly employed in patent applications, such as: 
so dimensioned, about, approximately, substantially, essen-
tially, consisting essentially of, comprising, and effective 
amount. 
Further, any publications, patent applications, patents, and 
other references mentioned herein are incorporated by refer-
ence in their entirety as if they were part of this specification. 
However, in case of conflict, the present specification, includ-
ing any definitions, will control. In addition, the materials, 
methods and examples given are illustrative in nature only 
and not intended to be limiting. 
Accordingly, this invention may be embodied in many 
different forms and should not be construed as limited to the 
illustrated embodiments set forth herein. Rather, these illus-
sis of ovarian tumor in vivo. Double of staining CD31 and 30 
TUNEL was performed as described in methods. First panel 
depicts CD31-FITC labeled endothelial cells as part of a 
microvessel (red). Second panel depicts the same microvessel 
stained positive for apoptotic marker TUNEL labeled with 
35 
FITC (green). Third panel shows blue nuclei stained with 
DAPI, indicating presence of tumor cells. The last panel 
shows merged image of all first three panels. The microvessel 
appears yellowish due to co-localization of CD31 and 
TUNEL. 40 trated embodiments are provided so that this disclosure will 
be thorough, complete, and will fully convey the scope of the 
invention to those skilled in the art. Other features and advan-
tages of the invention will be apparent from the following 
FIG. 9: NCe has no effect on cell proliferation of ovarian 
cancer cell lines. 5xl04 cells of A. A2780, B. C200 and C. 
SKOV3 were plated in 24 wells, treated with indicated doses 
ofNCe for 72 h, followed by exposure to [3H]-thymidine for 
6 hand subsequent radioactive counts. The data is represen- 45 
tation of three separate experiments done in triplicates. NS, 
non-significant compared with control. 
detailed description, and from the claims. 
Materials and Methods 
Reagents and Antibodies: 
Trypan Blue and MIT 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyl tetrazolium bromide) and HB-EGF were from 
Sigma. SDFl, VEGF165 and HGF were purchased from 
FIG. 10: Xenografts. Provides a representative photomi-
crograph of H&E staining (200x) of A2780 xenografts at day 
30. 
FIG. 11: NCe treatment is non-toxic in nude mice bearing 
human A2780 carcinoma. After sacrificing animal groups, 
organs of five mice from each group were formalin fixed, 
processed for histological sectioning and stained with H&E 
50 R&D Systems (MN, USA). Ki-67 antibody was purchased 
from Dako (Glostrup, Denmark) and VEGF antibody was 
purchased from Abeam (MA, USA). CD31 (PECAM) was 
from Santa Cruz Biotechnology (CA, USA). 
to observe morphology of the tissue. Representative photo- 55 
micrographs (lOOx) of A. Liver; B. Heart; C. Spleen; D. 
Kidney and E. lungs, show normal morphological architec-
ture in tissues of both untreated and NCe treated mice. 
FIG. 12: NCe does not affect the production ofVEGF and 
IL8 in SKOV3 cells. SKOV3 cells were plated and kept under 60 
serum free conditions overnight before being stimulated by 
EGF. Post 24 h supernatant was collected to perform ELISA. 
A. VEGF levels. B. IL18 levels. *p<0.01, **p<0.001 ofEGF 
treated to no treatment. NS=non-significant NCe treated to 
untreated; ns=non-significant NCe/EGF treated to EGF 65 
treated C. Representative photomicrograph ofVEGF staining 
( 400x) in A2780 xenografts at day 30 
Cell Culture: 
Human ovarian cancer cell lines SKOV3 and HUVEC 
were from American Type Culture Collection. A2780 and 
C200 cell lines were a kind gift of Dr. Tom Hamilton (Fox 
Chase Cancer Center). All cell lines were maintained and 
cultured in complete RPMI media containing 10% FBS, anti-
biotics. HUVEC cells were maintained in EBM-2 media pur-
chased from Lonza (Denmark). 
Nanoparticle Synthesis: 
Cerium Oxide nanoparticles were prepared by wet chemi-
cal synthesis as described previously {Karakoti, 2007 #30; 
Karakoti, 2008 #31; Karakoti, 2009 #24}. Briefly, cerium 
nitrate hexahydrate was dissolved in deionized water and then 
filtered using a 200 nm filter to get rid of any freely suspend-
US 8,916,199 Bl 
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NCe for 72 h. Each group was treated with ltYCi of [3 H] 
thymidine in the same medium for 6 h. The adherent cells 
were fixed by 5% trichloroacetic acid and lysed in SDS/ 
NaOH lysis buffer. Radioactivity was easured by Beckman 
LS3801 liquid scintillation counter (Canada). 
Colony Formation Assay: 
2000 cells were plated in triplicates in 6-well plates and 
treated with indicated concentrations ofNCe. The cells were 
allowed to form colonies for up to 2-4 weeks (depending on 
ing particulates. The solution containing cerium ions was 
then oxidized using hydrogen peroxide and ammonium 
hydroxide. The pH of the solution was adjusted between 
3.5-4.0 by using nitric acid or ammonium hydroxide. All the 
glasswares were autoclaved before being used for synthesis. 5 
The pH and the zeta potential of the suspension were closely 
monitored as the solution was allowed age at room tempera-
ture for next several days until the formation of nanoparticles 
with predominantly Ce3+ concentration was observed using 
UV-Visible spectrophotometry. 10 the cell line) and media was replaced every fourth day. 
Nanoparticles Characterization: 
Change in the oxidation states of the as-prepared nanopar-
ticles in solution was monitored using UV-Visible spectro-
photometry. Aliquots from the parent sample were taken for 
absorbance measurements by using Perkin Elmer 7 50 S spec- 15 
trophotometer. The particle morphology and size distribution 
was studied using high-resolution transmission electron 
microscopy (HRTEM). The size of the nanoparticles in as 
prepared solution prior to use in in-vitro and in-vivo studies 
was also monitored using dynamic light scattering (DLS). 20 
The oxidation states of cerium in particles were confirmed 
using X-ray photoelectron spectroscopy (XPS). For High 
Resolution Transmission Electron Microscopy (HRTEM) a 
drop of suspension of nanoparticles was deposited on the 
carbon-coated copper grid. The HRTEM images of the as- 25 
prepared particles were obtained with a Philips (Tecnai 
Series) operateding at 300 keV. The XPS data were obtained 
using a 5400 PHI ESCA (XPS) spectrometer. Samples were 
drop casted on a silicon wafer and dried inside a nitrogen 
glove box to avoid the oxidation of cerium from atmospheric 30 
oxygen and transferred using a sample transfer chamber with-
out exposing the samples to atmosphere. Only limited scans 
were obtained to avoid x-ray damage of cerium. An initial 
scan was saved separately to compare with the combined 5 
scan results and showed no difference in the Ce3 +/Ce4 + ratio. 35 
The base pressure during XPS analysis was 10-9 Torr and 
Mg-Ka X-ray radiation (1253.6 eV) at a power of200 W was 
used as x-ray source. The binding energy of Au (4f712) at 
84.0±0.1 eV was used to calibrate the binding energy scale of 
the spectrometer. Any charging shift produced in the spec- 40 
trum was corrected by referencing to the C (1 s) position at 
(284.6 eV) [13]. XPS spectra smoothing and baseline sub-
traction was carried out using PeakFit (Version 4) software. 
Migration and Invasion Assays: 
SKOV3 cells were grown in serum-free media overnight. 45 
Cell migration and invasion were measured as described [15] 
with modifications. Briefly, cell suspensions (500 µl, 2.5xl04 
cells) were seeded on the top of uncoated (migration assay) 
and Matrigel-coated (invasion assay) transwell plates (8-µm 
pore diameter; BD Biosciences). Serum-free cell suspensions 50 
(500 µl) were added to the top chamber of the transwell. The 
lower chambers contained serum free media containing vari-
ous growth factors including SDFl, HB-EGF, VEGF165 and 
HGF at the concentration of 25 µg/ml. Cells invading the 
lower chamber were stained with 0.5% crystal violet (60% 55 
PBS, 40% EtOH) and counted with an inverted microscope. 
The results from at least two independent experiments in 
triplicate are presented. 
Proliferation Assays: 
(i) MTT assay: 2.5-5.0xl04 cells were plated in 24 well 60 
plates in triplicates and treated with indicated concentrations 
of NCe for 72 h. MTT assay was performed as described 
before [16], to ascertain the number oflive cells. (ii) Thymi-
dine assay: Proliferation of cells was also determined by 
[
3H]-thymidine incorporation into DNA as described before 65 
[17]. In brief, 2.5-5.0xl04 cells were plated in 24 well plates 
in triplicates and treated with indicated concentrations of 
Formed colonies were stained with MTT and counted as 
described before [16]. 
Measurement of ROS: 
ROS were determined using the membrane-permeable 
fluorescent dye 6-carboxy 2',7'-dichlorodihydrofluorescein 
diacetate (DCFDA) in serum-free medium as described pre-
viously [ 18, 19]. The cultured cells, with or without treatment 
with NCe, were treated with 5 µM DCF dye in PBS and 
change in fluorescence was recorded at excitation 485 nm and 
emission 530 nm for various time period from 10 to 60 min 
using a Soft Max Pro spectrofluorometer (Molecular Devices, 
Surmyvale, Calif.). 
Western Blot: 
After stipulated time of incubation in the presence or 
absence ofindicated amounts ofNCe, andimmunoblot analy-
sis with specific antibodies was performed as previously 
described [16, 17, 18, 19]. In brief, treated and untreated 
HUVEC cells with VEGF165 (25 ng/ml) and/or NCe at vari-
ous time period (5-30 min) were lysed in lysis buffer (50 mM 
Tris-HCl (pH 7 .5), 250 mM NaCl, 5 mM EDTA, 50 mM NaF, 
and 0.5% Nonidet P-40] containing a protease inhibitor cock-
tail (Sigma). 50 µg of proteins were resolved by SDS-PAGE 
and transferred onto nitrocellulose membrane. The mem-
brane was then blocked for 1 h in 5% nonfat dry milk TTBS 
(20 mM Tris, 500 mM NaCl, and 0.1%Tween20, pH 7 .5) and 
incubated overnight in primary antisera (p VEG FR and ~ 
actin) containing 5% nonfat dry milk or 5% BSA in case of 
phospho-antibodies. Blots were washed with TTBS (four 
times, 5 min each) and incubated for 45 min at room tempera-
ture. HRP-conjugated anti-rabbit or anti-mouse secondary 
Ab was added at a dilution of 1/5000. The blots were washed 
three times in TTBS and developed with an ECL detection 
system (GE Healthcare, Piscataway, N.J.). 
In Vitro Vascular Tube Formation Assay: 
In vitro tube formation assays were performed as described 
by Melinda et. al. [20]. In brief, matrigel matrix was uni-
formly plated onto 8-well chamber slides (0.15 ml) and incu-
bated at 37° C. for 30 min. Trypsinized HUVEC cells sus-
pended in growth factors free medium. The cells were 
counted and diluted to 2x 105 /ml in medium. To set up the tube 
formation assay, cells were treated with NCe (25-50 µM) and 
mixed with cells in the presence or absence ofVEGF 165 (25 
ng/ml) and transferred to each well (200 µl) coated with 
matrigel. The plates or slides were incubated at 37° C. for 16 
h and imaged under a phase contrast inverted microscope at 
!Ox objective magnification. 
Zymography Assay: 
For MMP2 activity, HUVEC cells will be treated 
VEGF165 (25 ng/ml) in the presence or absence of NCe 
(25-50 µM). Post 18 h, cell supernatant was collected centri-
fuged at 12,000 g and 25 µl mixed with 5xSDS loading buffer 
without reducing agent and ran on 10% tris-glycine gel con-
taining gelatin. Gel was washed twice for 1 h with renaturat-
ing solution (2.5% TritonXl 00® in 50 mM tris pH 7.4, 5 mM 
CaCl, 1 mM ZnC12 ) to remove SDS and renature MMPs. 
After rinsing gel with deionized water, gel was incubated 
overnight at 37° C. with 50 mM tris pH 7.4, 5 mM CaCl, 1 
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mM ZnC12 . Next day, gel was stained with 0.5% Coomassie 
G250 followed by de-staining to see MMP2 activity in gel. 
Animals: 
Mice were maintained according to Institutional IACUC-
approved protocol. Mice ( 6-7 weeks old) were randomized 5 
into two groups and 2xl06/200 µl cells in PBS were injected 
into the intraperitoneal cavity (day 0) as described before 
[21]. NCe treatment at the dose of 0.1 mg/kg body weight 
began 3 days post inoculation of cells and given intraperito-
neally at every 3d day till end of the study. Mice were sacri- 10 
ficed at 4 weeks and tumors were fixed in formalin for sec-
10 
could also be induced by the drying process. The hydrody-
namic radius (37.8 nm±0.8) from the multimodal size distri-
bution (volume %) analysis of DLS measurements agrees 
with the loose agglomerate size of the HRTEM analysis. High 
magnification image confirms the (111) lattice planes ofNCe 
in individual 3-5 nm crystallites. UV-Visible spectroscopy 
was used to analyze the oxidation states of cerium oxide 
nanoparticles before and after aging treatment. FIG. 2 shows 
the UV-Visible spectra from fresh and aged cerium oxide 
nanoparticles clearly indicating the predominance of ce+3 
oxidation state from the absorption peak at 252 nm as com-
pared to absorption peak at 298 nm for Ce4 +. Further confir-
mation on the oxidation states ofnanoparticles was obtained 
from XPS analysis. The XPS spectrum of cerium is very 
tioning. Blood was collected in heparin to obtain plasma. 
Liver, kidney, heart and spleen from all animals were forma-
lin fixed and processed. One tumor and organ slide from each 
mouse was stained with H&E. 
Cytotoxicity Assays: 
Blood was collected in heparin coated tubes just before 
mice were sacrificed. Plasma isolated from blood of six mice 
from each group was subjected to analysis of a panel of liver 
function tests (aspartate aminotransferase; alanine ami-
notransferase; albumin) and kidney function tests ( creatinine; 
urea; albumin) as described before [21]. All assays were 
performed using kits from Bioassay Systems (CA, USA). All 
assays were performed according to the manufacturer's 
instructions. 
15 complex that contains multiple peaks from the spin orbit 
coupling of 3d orbitals {Deshpande, 2005 #10}. Several 
peaks in the Ce3d region that have been ascribed to 3d312 
(899.5, 900.9, 903.5, 906.4 and 916.6) and 3d512 (880.2, 
882.1, 8885, 888.1 and 898) arising from multiple valence 
20 states of cerium. The spectrum from NCe shows a predomi-
nance of cerium in +3 oxidation state as depicted by the 
characteristic peaks at 880.2, 885.0, 899.5 and 903.5 eV. 
Taken together the data from characterization ofNCe is con-
sistent with previous reports wherein cerium can be retained 
IHC: 
25 in trivalent oxidation by decreasing the size of the nanopar-
ticles {Deshpande, 2005 #10; Karakoti, 2007 #30; Karakoti, 
2008 #31; Karakoti, 2009 #24}. Fixed tumors excised from mice were processed for immu-
nohistochemistry for CD31, Ki-67 and TUNEL (Millipore) 
according to the manufacturer's protocol and described 
before [21]. H&E staining was performed by Mayo immuno-
histochemical core facilities. Ki-67 and H&E sections were 
examined under light microscope and representative picto-
grams were taken from 5 different slides of each group. For 
CD31 staining, TRITC-labeled secondary antibody was used 
and visualized using fluorescent microscope. For double 35 
staining, the slides were first processed for CD31 staining 
followed by an immunofluorescence TUNEL staining proto-
col according to manufacturer's instructions. 
Cerium oxide nanoparticles, including NCe have been 
shown to act as a free radical scavengers and as a result by 
30 inhibitsing the production ofreactive oxygen species (ROS) 
production [3, 4, 5]. Since, it is well established that ROS 
accumulation plays an important role in initiation and pro-
gression of tumorigenesis in human ovarian cancer [22, 23, 
Live Tumor Measurements: 
H&E stained xenograft sections were observed by a 40 
pathologist. Maximum diameter of viable tumor was calcu-
lated by summing the largest uni-dimensional diameter of 
each fragment of tumor using the Olympus® BX-41 micro-
scope and a micrometer. Similarly, necrotic areas were mea-
sured and the composite live tumor size was calculated from 45 
each slide. 
HUVEC Tube Formation: 
Statistical Analysis: 
24], we examined the effect of NCe on ROS generation in 
ovarian cancer cell line. For this, A2780 cell line was treated 
with NCe (50-100 µM). Post 48 h of treatment, ROS genera-
tion was measured using DCFH2-DA dye followed by fluo-
rescence reading. As shown in FIG. lD-E, NCe treatment 
significantly inhibited ROS levels inA2780 cell line, suggest-
ing that NCe treatment inhibits basal levels of oxidative stress 
in ovarian cancer cell line. 
Nee Did not Affect Cell Proliferation in Ovarian Cancer Cell 
Lines: 
We further examined the effect ofNCe on ovarian cancer 
growth in vitro. For this, various ovarian cancer cell lines 
(A2780, C200 and SKOV3) were plated in 96 well plates at 
4xl03 cells/well and treated with various concentrations of 
NCe (25-200 µM). Cell viability was determined at 72 hrs by 
MTT assay. As shown in FIG. 2A, NCe treatment had no The data were statistically analyzed using two-tailed Stu-
dent's t-test (Prism) or the Student-Newman-Keuls test 
(GraphPad Software). ***P<0.001; **P<0.01,*P<0.05; NS: 
not significant compared to untreated cells. 
Results 
50 significant effect on the proliferation or survival of ovarian 
cancer cell lines. To confirm this observation, we also per-
formed clonogenic assay (FIG. 2B) and found similar obser-
vation further confirming that NCe did not affect cell prolif-
eration of ovarian cancer cells. To further substantiate these Synthesis and Characterization of Cerium Oxide Nanopar-
ticles and its Effect on ROS Levels in Ovarian Cancer Cell 55 
Line: 
results, we also determined proliferation using [3H] thymi-
dine uptake in A2780, C200 and SKOV3 cells (FIG. Sl), 
observing the same. Similar results were obtained in addi-
tional ovarian cancer cell lines including Caov3 and TOV21 G 
(data not shown). Overall, NCe treatment did not significantly 
60 inhibit the growth of ovarian cancer cells lines in vitro. 
As prepared cerium oxide nanoparticles in this study con-
tains individual crystallites of3-5 nm that are loosely agglom-
erated to 15-25 nm. As the synthesis process is free from any 
organic surfactant the hard agglomeration of nanoparticles is 
controlled by tightly controlling the pH of the nanoparticles 
below 3.5 during synthesis to keep them in colloidal range. 
Nanoparticles can be diluted in aqueous or cellular media 
after the synthesis. FIGS. 1 a and b shows the high resolution 
transmission electron micro graphs (HRTEM) of NCe nano- 65 
particles. It is evident from the image that nanoparticles are 
loosely agglomerated to about 15-25 nm aggregates which 
NCe Inhibited Growth Factor-Mediated Cell Migration and 
Invasion in Vitro: 
We further evaluated the effect ofNCe on ovarian cancer 
cell migration and invasion in vitro. For this, we used SKOV3 
cells, which are known to migrate and invade proficiently in 
presence of growth factors (SDFl, HB-EGF, VEGF165 and 
HGF). Growth factors (GF) have been shown to play impor-
US 8,916,199 Bl 
11 
tant roles in the progression of ovarian cancer including peri-
toneal dissemination and invasion [25]. SKOV3 cells grown 
overnight in low serum (0.2%) containing medium were 
scratched using a sterile 200 µl pipette tip, once they reached 
90% confluency. Various growth factors including SDFl, 
HB-EGF, VEGF165 and HGF (25 µg/ml) were added indi-
vidually to the medium in the presence or absence of NCe 
(100 µM). 24 hrs later, the rate of wound closure was calcu-
lated. As depicted in FIG. 3A, NCe inhibited all growth factor 
mediated cell migration in SKOV3 cell line. Similar obser- 10 
vation was found in additional ovarian cancer cell lines 
(A2780 and C200) (data not shown). Next we assessed the 
effect ofNCe in inhibiting GP-mediated invasion of SKOV3 
cells using Boyden chamber migration assay (BD Bio-
science). FIG. 3B clearly demonstrates that NCe treatment 15 
significantly inhibited all growth factors induced invasion of 
SKOV3 cells compared to untreated cells. Thus, NCe has the 
ability to inhibit migration and invasion of ovarian cancer 
cells without effecting their proliferation. 
12 
excised from untreated and NCe treated mice at the end of the 
study, formalin fixed and processed for obtaining section 
slides. H&E staining was performed on these sections and 
studied by a pathologist. The morphological architectural 
structure of all organs from treated and untreated mice 
appeared to be normal and no necrosis was observed (FIG. 
llA-E; lOOx). Further, plasma was separated from blood 
collected in heparin coated tubes and analyzed for liver func-
tion tests (aspartate aminotransferase, AST; alanine ami-
notransferase, ALT; albumin) and kidney function tests ( crea-
tinine; blood urea nitrogen, BUN; albumin). No significant 
difference was observed between the untreated and NCe 
treated mice and all values were found within the normal 
limits in both groups (FIG. SA-E). No fluctuation in the 
glucose levels was observed either (FIG. SF). These data 
show that NCe treatment on every third day for 4 weeks at the 
dose of0.1 mg/kg is safe and does not result in tissue cyto-
toxicity or any abnormal physiological vital functions. 
NCe Inhibited Metastasis in Human A2780 Ovarian Carci-
NCe Treatment Attenuated Tumor Growth in Human A2780 
Ovarian Carcinoma Cell Line Bearing Nude Mouse Model: 
20 noma Cell Line Bearing Nude Mouse Model: 
We further investigated if NCe will be able to restrain in 
vivo growth and spread of the ovarian cancer using a preclini-
cal mouse model. For this, A2780 cells were injected intra-
peritoneally (IP) in athymic nu/nu mice to develop ovarian 25 
tumors. Mice were treated with NCe (0.1 mg/kg body weight) 
given intraperitoneally, every third day till end of the study 
(day 30) as described in the material and methods. FIG. 4A 
(top panel) shows a representative gross photograph of a NCe 
treated and untreated mouse bearing A2780 tumor at the end 30 
of study (day 30). The abdominal circumference, indicative 
Since our in vitro data showed that NCe treatment inhibited 
growth factor induced migration and invasion, we further 
examined for the presence of metastasis in various organs. 
Microscopic study of H&E sections from various organs 
revealed no invasion of tumor cells inside liver, spleen and 
kidney (data not shown), although tumor nodules were visible 
on their surface of untreated mice. However, only metastasis 
observed was in lungs. Large metastatic nodules were 
observed in lungs of untreated mice, which were significantly 
reduced in lungs ofNCetreatedmice. FIG. 6A (40x) shows a 
representative photomicrograph of metastatic nodules in the 
lungs isolated from untreated and treated mice. Along with 
the reduction in size of the metastatic nodules, the number of 
nodules was also significantly decreased by NCe treatment 
(FIG. 6B), indicating that as observed in vitro (Fig.), NCealso 
restricted migration and invasion of tumors cells in vivo. 
NCe Inhibited Angiogenesis in A2780 Ovarian Carcinoma 
Mouse Model: 
of the tumor burden in the peritoneum (FIG. 4B) and the 
tumor weight (FIG. 4C) in the NCetreatedmicewere signifi-
cantly (p<0.002) reduced compared to untreated mice. The 
mean weight of the excised tumors was approximately 33% 35 
less in NCe ( 4.56+0.345 gm) treated mice compared to 
vehicle (PBS) mice (6.79+0.53 gm) (FIG. 4C). This data 
clearly indicates that NCe has the ability to restrict ovarian 
tumor growth in vivo when administered at a low dose (0.1 
mg/kg). 
As we did not observe any significant effect on cell prolif-
40 eration or cell death in ovarian cancer cell lines in vitro but 
To examine how NCe affected the tumor growth in vivo, 
the excised tumor tissue was formalin fixed and processed for 
immunohisochemical evaluation. Representative H&E stain-
ing depicting A2780 tumor morphology is shown in FIG. Di 
(20x) Observation of H&E sections showed most of the cells 45 
to be live in untreated xenografts, while NCe treated had 
significantly more areas with dead (necrotic) cells (FIG. 4Di; 
20x; non-viable area encircled). To quantitate the live and 
dead areas in the xenograft sections, uni-dimensional mea-
surements of the viable tumor and total tumor size were taken 50 
as described in the methods section. As quantitated in FIG. 
4Dii, NCe treated tumors had less viable tumor size than the 
untreated mice. To see the status of proliferation in tumor 
cells, Ki-67 staining was performed. Significant difference 
was observed in the number of cells staining positive for 55 
Ki-67 (FIG. 4Ei). Enumeration of Ki-67 positive cells 
counted over 5 high power fields of five sections from each 
group also showed significant less Ki-67 positive cells in NCe 
treated xenografts compared to untreated group (expressed in 
found significant reduction in tumor growth in vivo, we fur-
ther investigated the underlying mechanism ofNCe mediated 
reduction of tumor size. For this we focused on angiogenesis 
as it is one the important factors implicated in progression of 
ovarian cancer [26,27]. Also for a tumor to sustain, grow, 
proliferate and invade, formation of new vasculature is a 
prerequisite. Microvessel density of tumors increases in 
response to various angiogenic factors and the low oxygen 
availability in the growing tumors, which enables them to 
avoid death and proceed to invasion and metastasis. We evalu-
ated the microvessel density by staining for CD31 in 
xenograft sections from A2780 bearing NCe treated and 
untreated mice. We found tumor treated with NCe exhibited 
significantly less number of CD31 positive microvessel as 
evident from the representative photomicrograph (FIG. SC, 
200x) and the quantification of positively stained vessels at 
high power read from 5 fields of five sections from each group 
(FIG. SD, 400x). These indicate that NCe maybe targeting 
angiogenesis and as a consequence limiting tumor growth. 
NCe Treatment Targets Angiogenesis by Inhibiting VEGF 
Signaling in Endothelial Cells: 
% age; FIG. 4E ii), indicating that less number of cells were 60 
proliferating under NCe treatment. Together, this data shows 
that NCe has the ability to restrict ovarian tumor growth in 
vivo due to decreased proliferation and increased non-viable 
tumor mass by an unknown mechanism as yet. 
VEGF is the most potent angiogenic factor that is produced 
by the tumor cells and is also overexpressed in ovarian tumors 
[28,29 ,30]. To investigate ifNCe treatment maybe restricting 
65 angiogenesis by inhibiting VEGF production/levels, we 
examined the effect ofNCe on VEGF production in SKOV3 
cells in vitro. SKOV3 cells were grown, kept in serum free 
NCe Treatment is Nontoxic In Vivo: 
We further examined the cellular toxicity ofNCe in vivo. 
Various organs (liver heart, spleen, kidney and lungs) were 
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conditions overnight and treated with EGF to stimulate 
VEGF production. Post 24 h supernatant was used to estimate 
the levels ofVEGF by ELISA. As shown in FIG. 12A, treat-
ment with EGF induced the production ofVEGF in SKOV3 
cells, while no changes were found in VEGF levels when cells 
were treated with NCe. Under similar experimental condi-
tions we also estimated the levels ofIL-8, which is involved in 
ovarian cancer pathogenesis and VEGF production [31]. 
Similar to VEGF, NCe did not affect the levels ofIL18 pro-
duction (FIG. 12B). As a further confirmation, we also 10 
immuno-stained for VEGF levels in the A2780 xenografts 
from NCe treated and untreated mice and observed no change 
in the VEGF expression (FIG.12C).All these findings clearly 
suggest that NCe does not modulate the VEGF levels in 
ovarian cancer cells (or other cytokines) but limits angiogen- 15 
esis by some other mechanism. 
Since NCe treatment significantly reduced the number of 
microvessels in treated tumor without affecting the VEGF 
expression, we wanted to investigate ifNCe modulates angio-
genesis signaling downstream ofVEGF in endothelial cells. 20 
For this, we examined the effect ofNCe on VEGF mediated 
signaling on HUVEC endothelial cells. First, we observed for 
the effect ofNCe on VEGF induced proliferation ofHUVEC 
cells by thymidine incorporation, which was significantly 
attenuated by NCe treatment (FIG. 7A). The next step for 25 
proliferating endothelial cells is to form new vessels. 
HUVEC cells (2xl 04 ) were plated on matrigel coated 96 well 
plate in the presence of NCe (25-50 µM) with or without 
VEGF 165 (25 ng/ml) as angiogenic stimuli. Morphology of 
the cells in matrigel was examined after 18 h of incubation 30 
under an inverted microscope to observe for tube formation. 
VEGF 165 induced endothelial tube formation was signifi-
cantly retarded by NCe treatment (FIG. 7B). NCe treatment 
also reduced the phosphorylation ofVEGFR2 at Tyrl 175 in 
HUVEC cells in response to VEGF165 treatment (FIG. 7C), 35 
which is critical for proliferation and the recruitment of adap-
tor proteins including p85 of PB Kinase and PLCy [32]. It also 
attenuated phosphorylation ofVEGFR2 at Y951, which is an 
autophosphorylation site that leads to recruitment of adaptor 
proteins, including She, Grb2, PI-3 kinase, Nck and the pro- 40 
tein tyrosine phosphatases SHP-1 and SHP-2 [33]. NCe also 
inhibited VEGF induced MMP2 activity in endothelial cells 
as determined by zymography assay (FIG. 7D). These data 
clearly suggest that NCe treatment inhibits VEGF mediated 
downstream signaling in endothelial cells and as a result may 45 
interfere with proliferation and survival of endothelial cells. 
NCe Treatment Specifically Targets Endothelial Cells In 
Vivo: 
14 
interest in various animal models, especially in the field of 
cancer [34,35]. Successful incorporation of nanoparticles as 
anti-cancer therapeutics can open an entirely new avenue for 
cancers like ovarian, where chemotherapeutic options are 
limited and high mortality is a serious concern. In this regard 
we investigated the potential of a unique cerium oxide nano-
particles, (nanoceria; NCe) as a therapeutic agent in ovarian 
cancer. 
In the present study, we show for the first time that NCe has 
the potential to inhibit ovarian tumor growth and metastasis. 
We show that NCe attenuated basal levels of oxidative stress, 
invasion and migration of ovarian cancer cells without modu-
lating their cell growth. It also significantly attenuated tumor 
growth in A2780 bearing nude mice when given intraperito-
neally. Our study found a novel property of NCe as anti-
angiogenic as its treatment reduced the microvessel density in 
ovarian xenografts, inhibited proliferation and induced apo-
ptosis in endothelial cells in vitro and in vivo respectively, and 
also attenuated VEGF mediated downstream signaling in 
HUVEC. In vivo treatment ofNCe resulted in specific apop-
tosis of endothelial cells in the microvessels being formed in 
the tumor tissue. Overall, our study presents novel property of 
NCe as an anti-angiogenic agent for its use in ovarian cancer. 
The most attractive property of cerium oxide nanoparticles 
is their capacity to serve as free radical scavengers to provide 
protection against chemical, biological, and radiological 
insults that promote the production of free radicals [3,4,5]. 
NCe offers many active sites for free radical scavenging due 
to its large surface/volume ratio and mixed valence states ( +4 
and +3) for unique redox chemistry. Moreover, its unique 
regenerative property (Ce3+-Ce4 +---Ce3 +) [4] makes NCe 
long-lived and can confer their beneficial effect for extended 
periods of time without redosing. It is reported recently NCe 
selectively conferred radioprotection to the normal cells 
(CRL 8798) against ROS compared to the breast cancer cells 
[5]. It also confers radioprotection against pneumonitis and 
gastrointestinal epithelium by reducing ROS [36,37]. 
Another recent study showed NCe to bestow protection from 
monocrotaline-induced hepatoxicity due to oxidative stress 
[38]. Our finding showed that NCe acts as an anti-oxidant in 
ovarian cancer is in agreement with these previous reports. 
However, NCe has been shown to induce oxidative stress in 
other cancer cell lines including human bronchoalveolar car-
cinoma derived cell line ( A54 9) and squamous SCL-1 tumor 
cell line [39]. These reports suggest that cerium oxide par-
ticles may have differential anti-oxidant properties dependent 
on the nature of cell type. In our study, although the anti-
oxidant property of NCe was able to reduce basal levels of 
oxidative stress but failed to inhibit proliferation of ovarian To investigate if NCe has inhibitory effect on vessel for-
mation in vivo as observed in vitro, we performed double 
staining with CD31 and TUNEL in the xenograft slides from 
both treated and untreated mouse groups. As shown in FIG. 8, 
CD31 recognized endothelial cells in the microvessels 
(stained red, first panel). Cells undergoing apoptosis were 
detected by performing TUNEL staining (stained green, sec-
ond panel). Upon superimposing, it was observed that 
TUNEL and CD31 stains were colocalized (yellowish, last 
panel), indicating that it was the endothelial cells specifically 
50 cancer cell lines in vitro. Interestingly, NCe inhibited growth 
factor induced migration and invasion of ovarian cancer cell 
lines. Similar to our observation, Tarnuzzer et al [5] also 
found non-cytotoxic effect of NCe on MCF7 breast cancer 
cell line. However, polymer-coated NCe showed cytotoxic 
55 effect on squamous tumor SCL-1 cells [39]. The discrepancy 
between our and other [39] reports may be due to any change 
in surface properties of nanoparticles in various cell types the 
difference between the preparation and nature of nanopar-
in the microvessels that were undergoing apoptosis under 
NCe treatment. These data suggest a potential role for NCe as 60 
an anti-angiogenic molecule that acts by targeting endothelial 
cells and VEGF signaling. 
ticles and cell type. 
On observing that NCe treatment inhibited GF induced 
migration/invasion in vitro, we examined its ability to modu-
late tumor growth in vivo. We found that administration of 
NCe (0.1 mg/kgbdwt) on every third day significantly 
retarded A2780 xenograft growth in vivo which was also 
Discussion 
The science of developing nanoparticles into nanomedi-
cine to encounter human diseases for better health outcomes 
is a rapidly progressing field. A number of metal nanopar-
ticles have been designed and shown to be of therapeutic 
65 accompanied by attenuation of metastatic nodule size and 
number in lung. This is the first report that demonstrates the in 
vivo ability of NCe to inhibit ovarian tumor growth and 
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metastasis. Also, this dose ofNCe is well tolerated by mice 
without any cytotoxic or adverse physiological effects 
observed in the vital organs. These findings are in agreement 
of previous report where NCe upto 135 mg/kg body weight 
did not cause any death or notable side effect in nude mice 5 
with normal pathology of vital organs [36]. However, a recent 
report indicates the toxic effect of NCe in rodents [ 40]. This 
can be accounted for as the dose ofNCe used in the previous 
study is 1000-2500 times higher (100-250 mg/kg body 
weight) then what we have used in our study (0.1 mg/kg body 10 
weight) [40]. 
Although in vitro, NCe treatment did not affect ovarian 
cancer cell growth, but we observed lesser staining ofKi-67, 
a maker of cell proliferation, suggesting NCe treatment might 
be affecting the tumor micro-environment rather than having 15 
a direct effect on tumor cells. To determine the mechanism by 
which NCe maybe restricting tumor growth, we examined the 
microvessel density in treated and untreated tumor and found 
a significant reduction in NCe treated tumor as evident from 
CD31 staining, a marker for endothelial cells. Interestingly, 20 
NCe did not modulate the production ofVEGF production in 
vitro and in vivo. These observations led us to hypothesize 
that NCe maybe specifically targeting the endothelial cells 
responsible for formation of new vessels. 
Angiogenesis is important for tumor development and 25 
growth and VEGF has been shown to be a major angiogenesis 
inducer primarily through the VEGF type 2 receptor 
(VEGFR2) [41,42]. VEGF binding initiates autophosphory-
lation ofVEGFR2, which, in turn, creates docking sites for 
Src homology domain 2-containing adaptor molecules. This 30 
event is followed by activation of diverse key angiogenic 
enzymes including MMP2. We observed that NCe treatment 
inhibited VEGF induced proliferation, capillary tube forma-
tion and MMP2 activation in endothelial cells. NCe treatment 
attenuated VEGF mediated phosphorylation of VEGFR2 35 
(Y1175 and Y951), a prerequisite for VEGF to signal to 
endothelial cells. Phosphorylation of VEGFR2 (Yl 175) is 
critical for endothelial proliferation and the recruitment of 
adaptor proteins including p85 of PB Kinase and PLCy [32] 
16 
folate receptor over expressed in ovarian cancer, as a tool to 
deliver NCe specifically to tumor as a novel therapy. More-
over, NCe could be conjugated with other chemotherapeutic 
drugs for their specific delivery as well as enhancement of 
their cytotoxicity, while reducing the side effects. The out-
come of these studies could open a new and novel avenue of 
therapy for ovarian cancer. 
Accordingly, in the drawings and specification there have 
been disclosed typical preferred embodiments of the inven-
tion and although specific terms may have been employed, the 
terms are used in a descriptive sense only and not for purposes 
of limitation. The invention has been described in consider-
able detail with specific reference to these illustrated embodi-
ments. It will be apparent, however, that various modifica-
tions and changes can be made within the spirit and scope of 
the invention as described in the foregoing specification and 
as defined in the appended claims. 
REFERENCES 
1. Bast RC, Jr., Urban N, Shridhar V, Smith D, Zhang Z, et al. 
(2002) Early detection of ovarian cancer: promise and real-
ity. Cancer Treat Res 107: 61-97. 
2. Friedlander ML (1998) Prognostic factors in ovarian can-
cer. Semin Oncol 25: 305-314. 
3. Chen J, Patil S, Seal S, McGinnis J F (2006) Rare earth 
nanoparticles prevent retinal degeneration induced by 
intracellular peroxides. Nat Nanotechnol 1: 142-150. 
4. Das M, Patil S, Bhargava N, Kang J F, Riedel L M, et al. 
(2007) Auto-catalytic ceria nanoparticles offer neuropro-
tection to adult rat spinal cord neurons. Biomaterials 28: 
1918-1925. 
5. Tamuzzer R W, Colon J, Patil S, Seal S (2005) Vacancy 
engineered ceria nanostructures for protection from radia-
tion-induced cellular damage. Nano Lett 5: 2573-2577. 
6. Patil S, Sandberg A, Heckert E, Self W, Seal S (2007) 
Protein adsorption and cellular uptake of cerium oxide 
nanoparticles as a function of zeta potential. Biomaterials 
28: 4600-4607. 
and phosphorylation of VEGFR2 at Y951 is important for 40 7. Carmeliet P, Jain R K (2000) Angiogenesis in cancer and 
recruitment of adaptor proteins [33]. Inhibition of VEGF other diseases. Nature 407: 249-257. 
induced downstream signaling including proliferation, tube 
formation and MMP2 activation by NCe treatment indicating 
a novel anti-angiogenic property ofNCe. Targeting of endot-
helial cells by NCe in vivo was also supported TUNEL assay 45 
in NCe treated xenografts specific to CD31+ve endothelial 
cells. The role of oxidative stress in angiogenesis is an emerg-
ing area of investigation [ 43]. An anti-angiogenic property of 
NCe might be modulating VEGF mediated signaling events 
which are redox sensitive [ 42]. This is the first report demon- 50 
strating any cerium oxide nanoparticles to exhibit an anti-
angiogenic property with specificity for endothelial cells. 
Anti-angiogenic agents have demonstrated activity in 
terms of both response and progressive free survival (PFS) in 
phase II and phase III clinical trials for women with epithelial 55 
ovarian cancer, both in the front-line and relapsed setting [ 44, 
45, 46, 47]. But recent emerging reports indicate the therapy 
to be associated with increased fatal reactions [ 48, 49, 50, 51]. 
Therefore, novel strategies and agents that can target angio-
8. Kerbel R, Folkman J (2002) Clinical translation of angio-
genesis inhibitors. Nat Rev Cancer 2: 727-739. 
9. Ferrara N (1996) Vascular endothelial growth factor. Eur J 
Cancer 32A: 2413-2422. 
10. Macchiarini P, Fontanini G, Hardin M J, Squartini F, 
Angeletti CA (1992) Relation of neovascularisation to 
metastasis of non-small-cell lung cancer. Lancet 340: 145-
146. 
11. Paley P J, Staskus KA, Gebhard K, Mohanraj D, Twiggs 
L B, et al. (1997) Vascular endothelial growth factor 
expression in early stage ovarian carcinoma. Cancer 80: 
98-106. 
12. Weidner N, Carroll PR, Flax J, Blumenfeld W, Folkman 
J (1993) Tumor angiogenesis correlates with metastasis in 
invasive prostate carcinoma. Am J Pathol 143: 401-409. 
13. Weidner N, Semple JP, Welch WR, Folkman J (1991) 
Tumor angiogenesis and metastasis--correlation in inva-
sive breast carcinoma. N Engl Med 324: 1-8. 
genesis without many side effects are still required. 
Taken together, our results reveal a new role of cerium 
oxide nanoparticles as a novel, non-toxic anti-angiogenic 
agent which restricted ovarian tumor growth in preclinical 
mouse model of ovarian cancer. Our study opens up a new 
avenue of using nanoparticles as feasible therapeutics in ova-
rian cancer. A future option to increase the efficacy and speci-
ficity ofNCe can be conjugating it with folic acid, a ligand for 
60 14. Burger RA, Sill MW, Monk BJ, Greer BE, Sorosky JI 
(2007) Phase II trial ofbevacizumab in persistent or recur-
rent epithelial ovarian cancer or primary peritoneal cancer: 
a Gynecologic Oncology Group Study. J Clin Oneal 25: 
5165-5171. 
65 15. Narita K, Staub J, Chien J, Meyer K, Bauer M, et al. 
(2006) HSulf-1 inhibits angiogenesis and tumorigenesis in 
vivo. Cancer Res 66: 6025-6032. 
US 8,916,199 Bl 
17 
16. RattanR, Girl S, HartmannL C, ShridharV (2011) Met-
formin attenuates ovarian cancer cell growth in an AMP-
kinase dispensable manner. J Cell Mo! Med 15: 166-178. 
17. Rattan R, Giri S, SinghA K, Singh I (2005) 5-Aminoimi-
dazole-4-carboxamide-l-beta-D-ribofuranoside inhibits 5 
cancer cell proliferation in vitro and in vivo via AMP-
activated protein kinase. J Biol Chem 280: 39582-39593. 
18. Giri S, Khan M, Nath N, Singh I, Singh AK (2008) The 
role of AMPK in psycho sine mediated effects on oligoden-
drocytes and astrocytes: implication for Krabbe disease. J 10 
Neurochem 105: 1820-1833. 
19. Giri S, Khan M, Rattan R, Singh I, Singh AK (2006) 
Krabbe disease: psycho sine-mediated activation of phos-
pholipaseA2 in oligodendrocyte cell death. J Lipid Res 4 7: 
1478-1492. 15 
20. Malinda KM, Sidhu GS, Mani H, Banaudha K, Mahesh-
wari R K, et al. (1999) Thymosin beta4 accelerates wound 
healing. J Invest Dermatol 113: 364-368. 
21. Rattan R, Graham R P, Maguire J L, Giri S, Shridhar V 
(2011) Metformin suppresses ovarian cancer growth and 20 
metastasis with enhancement of cisplatin cytotoxicity in 
vivo. Neoplasia In Press. 
22. Chan D W, Liu V W, Tsao GS, Yao KM, Furukawa T, et 
al. (2008) Loss of MKP3 mediated by oxidative stress 
enhances tumorigenicity and chemoresistance of ovarian 25 
cancer cells. Carcinogenesis 29: 1742-1750. 
23. Liu L Z, Hu X W, Xia C, He J, Zhou Q, et al. (2006) 
Reactive oxygen species regulate epidermal growth factor-
induced vascular endothelial growth factor and hypoxia-
inducible factor- I alpha expression through activation of 30 
AKT and P70S6Kl in human ovarian cancer cells. Free 
Radie Biol Med 41: 1521-1533. 
24. Xia C, Meng Q, Liu L Z, Rojanasakul Y, Wang X R, et al. 
(2007) Reactive oxygen species regulate angiogenesis and 
tumor growth through vascular endothelial growth factor. 35 
Cancer Res 67: 10823-10830. 
25. Miyamoto S, Yagi H, Yotsumoto F, Horiuchi S, Yoshizato 
T, et al. (2007) New approach to cancer therapy: heparin 
binding-epidermal growth factor-like growth factor as a 
novel targeting molecule. Anticancer Res 27: 3713-3721. 40 
26. Gomez-Raposo C, Mendiola M, Barriuso J, Casado E, 
Hardisson D, et al. (2009) Angiogenesis and ovarian can-
cer. Clin Transl Oncol 11: 564-571. 
27. Markman M (2009) Antiangiogenic drugs in ovarian can-
cer. Expert Opin Pharmacother 10: 2269-2277. 45 
28. Lose F, Nagle CM, O'Mara T, Batra J, Bolton KL, et al. 
(2010) Vascular endothelial growth factor gene polymor-
phisms and ovarian cancer survival. Gynecol Oneal 119: 
479-483. 
29. Mesiano S, Ferrara N, Jaffe RB (1998) Role of vascular 50 
endothelial growth factor in ovarian cancer: inhibition of 
ascites formation by immunoneutralization. Am J Pathol 
153: 1249-1256. 
30. Tempfer C, Obermair A, Hefler L, Haeusler G, Gitsch G, 
et al. (1998) Vascular endothelial growth factor serum con- 55 
centrations in ovarian cancer. Ob stet Gynecol 92: 360-363. 
31. Xu L, Fidler I J (2000) Interleukin 8: an autocrine growth 
factor for human ovarian cancer. On col Res 12: 97 -106. 
32. Takahashi T, Yamaguchi S, ChidaK, Shibuya M (2001)A 
single autophosphorylation site on KDR/Flk-1 is essential 60 
for VEGF-A-dependent activation of PLC-gamma and 
DNA synthesis in vascular endothelial cells. Embo J 20: 
2768-2778. 
18 
34. Bharali DJ, Mousa SA (2010) Emerging nanomedicines 
for early cancer detection and improved treatment: current 
perspective and future promise. Pharmacol Ther 128: 324-
335. 
35. Seigneuric R, Markey L, Nuyten D S, Dubernet C, Evelo 
CT, et al. (2010) From nanotechnology to nanomedicine: 
applications to cancer research. Curr Mo! Med 10: 640-
652. 
36. Colon J, Herrera L, Smith J, Patil S, Komanski C, et al. 
(2009) Protection from radiation-induced pneumonitis 
using cerium oxide nanoparticles. Nanomedicine 5: 225-
231. 
37. Colon J, Hsieh N, Ferguson A, Kupelian P, Seal S, et al. 
(2010) Cerium oxide nanoparticles protect gastrointestinal 
epithelium from radiation-induced damage by reduction of 
reactive oxygen species and upregulation of superoxide 
dismutase 2. Nanomedicine 6: 698-705. 
38. Amin KA, Hassan MS, Awad el ST, Hashem KS (2011) 
The protective effects of cerium oxide nanoparticles 
against hepatic oxidative damage induced by monocrota-
line. Int J Nanomedicine 6: 143-149. 
39. Alili L, Sack M, KarakotiA S, Teuber S, Puschmann K, et 
al. (2011) Combined cytotoxic and anti-invasive properties 
ofredox-active nanoparticles in tumor-stroma interactions. 
Biomaterials. 
40. Hardas S S, Butterfield DA, Sultana R, Tseng MT, Dan 
M, et al. (2010) Brain distribution and toxicological evalu-
ation of a systemically delivered engineered nanoscale 
ceria. Toxicol Sci 116: 562-576. 
41. Folkman J (1971) Tumor angiogenesis: therapeutic impli-
cations. N Engl J Med 285: 1182-1186. 
42. Matsumoto T, Claesson-Welsh L (2001) VEGF receptor 
signal transduction. Sci STKE 2001: re21. 
43. Ushio-Fukai M, Nakamura Y (2008) Reactive oxygen 
species and angiogenesis: NADPH oxidase as target for 
cancer therapy. Cancer Lett 266: 37-52. 
44. Burger RA Overview of anti-angiogenic agents in devel-
opment for ovarian cancer. Gynecol Oneal. 
45. Cannistra SA, Matulonis U A, Penson RT, Hambleton J, 
Dupont J, et al. (2007) Phase II study of bevacizumab in 
patients with platinum-resistant ovarian cancer or perito-
neal serous cancer. J Clin Oncol 25: 5180-5186. 
46. Garcia AA, Hirte H, Fleming G, Yang D, Tsao-Wei DD, 
et al. (2008) Phase II clinical trial of bevacizumab and 
low-dose metronomic oral cyclophosphamide in recurrent 
ovarian cancer: a trial of the California, Chicago, and Prin-
cess Margaret Hospital phase II consortia. J Clin Oncol 26: 
76-82. 
4 7. Penson R T, Dizon D S, Cannistra S A, Roche M R, 
Krasner C N, et al. Phase II study of carboplatin, paclitaxel, 
and bevacizumab with maintenance bevacizumab as first-
line chemotherapy for advanced mullerian tumors. J Clin 
Oncol 28: 154-159. 
48. Bansal N, Hoffman M (2011) Bladder perforation in a 
patient with recurrent epithelial ovarian cancer after treat-
ment with bevacizumab. Gynecol Oncol 120: 313-314. 
49. Koskas M, Chereau E, Ballester M, Selle F, Rouzier R, et 
al. (2010) Wound complications after bevacizumab treat-
ment in patients operated on for ovarian cancer. Anticancer 
Res 30: 4743-4747. 
50. Lecarpentier E, Ouaffi L, Mir 0, Berveiller P, Maurel M, 
et al. (2010) Bevacizumab-induced small bowel perfora-
tion in a patient with breast cancer without intraabdominal 
metastases. Invest New Drugs. 33. Kroll J, Waltenberger J (1997) The vascular endothelial 
growth factor receptor KDR activates multiple signal 
transduction pathways in porcine aortic endothelial cells. J 
Biol Chem 272: 32521-32527. 
65 51. Randall L M, Monk B J Bevacizumab toxicities and their 
management in ovarian cancer. Gynecol Oneal 117: 497-
504. 
US 8,916,199 Bl 
19 
That which is claimed: 
1. A method of treating ovarian cancer in a mammal, the 
method comprising parenteral administration to the mammal 
of an effective amount of cerium oxide in nanoparticles hav-
ing a predominance of ce+3 . 
2. The method of claim 1, wherein the mammal is a human 
subject. 
3. The method of claim 1, wherein parenteral administra-
tion comprises intraperitoneal administration. 
4. The method of claim 1, wherein the effective amount 10 
comprises less than approximately 1 mg per kilogram ofbody 
weight of the mammal. 
5. The method of claim 1, wherein the effective amount 
comprises approximately 0.1 mg per kilogram ofbody weight 
of the mammal. 15 
6. The method of claim 1, wherein the effective amount is 
parenterally administered approximately every 72 hours. 
7. A method of inhibiting growth-mediated cell migration 
and invasion of mammalian ovarian cancer cells, the method 
comprising contacting the cells with an effective amount of 20 
cerium oxide nanoparticles having a predominance of Ce+3 . 
8. A method of inhibiting angiogenesis associated with a 
mammalian ovarian carcinoma, the method comprising con-
tacting the carcinoma with an effective amount of cerium 
oxide nanoparticles having a predominance of Ce+3 . 25 
9. The method of claim 8, wherein contacting the carci-
noma further comprises contacting vascular endothelial cells 
associated with the carcinoma. 
* * * * * 
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